Reduced Serum SRANKL and STREM2 Levels in High-Grade Gliomas: Association with Prognosis

Overview

Journal Noro Psikiyatr Ars

Date 2021 Jun 30

PMID 34188596

Citations 3

Authors

Mustafa Efendioglu

Elif Sanli

Ceren Turkoglu

Naci Balak

Affiliations

Soon will be listed here.

Abstract

Introduction: High-grade gliomas (HGG), including Glioblastoma multiforme (GBM), account for the majority of primary brain tumors. Nevertheless, prognostic and diagnostic biomarkers are quite limited for HGG. The objective of this study was to investigate the prognostic value of sRANKL and sTREM2 levels in HGG patients.

Methods: Twelve consecutive patients with HGG, 14 patients with non-glial tumors (non-GT) and 20 age and gender-matched healthy controls were recruited. Overall survival duration of the patients was recorded. Pre-operative serum levels of sRANKL and sTREM2 were measured by ELISA. Tumors of HGG patients were analyzed by immunohistochemical staining for p53 and Ki67 and percentage scores were calculated.

Results: Patients with HGG and non-GT showed lower serum sRANKL and sTREM2 levels than healthy individuals. Levels of sRANKL were inversely correlated with the overall survival of patients (p=0.002, R=0.787), while sTREM2 levels were inversely correlated with p53 score (p=0.018, R=-0.666) but not survival.

Conclusion: Brain tumor patients show suppressed levels of glial activity biomarkers in the peripheral circulation. Serum sRANKL levels may serve as a potential prognostic biomarker for HGG.

Citing Articles

Blood-based biomarkers: diagnostic value in brain tumors (focus on gliomas).

Yang Y, Hu F, Wu S, Huang Z, Wei K, Ma Y Front Neurol. 2023; 14:1297835.

PMID: 37936915 PMC: 10626008. DOI: 10.3389/fneur.2023.1297835.

TREM2 Is Associated with Advanced Stages and Inferior Prognosis in Oral Squamous Cell Carcinoma.

Struckmeier A, Radermacher A, Fehrenz M, Alansary D, Wartenberg P, Wagner M Cancers (Basel). 2022; 14(19).

PMID: 36230558 PMC: 9561992. DOI: 10.3390/cancers14194635.

Aquaporin-4 Gene Polymorphisms in Relapsing Inflammatory Optic Neuropathy and RANKL in Glioblastoma: Research and Progress on Biomarkers.

Sanli E, Tuzun E Noro Psikiyatr Ars. 2021; 58(2):81-82.

PMID: 34188586 PMC: 8214747. DOI: 10.29399/npa.27789.

References

Takahashi K, Rochford C, Neumann H . Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005; 201(4):647-57. PMC: 2213053. DOI: 10.1084/jem.20041611. View

Ahmadipour Y, Jabbarli R, Gembruch O, Pierscianek D, Oppong M, Dammann P . Impact of Multifocality and Molecular Markers on Survival of Glioblastoma. World Neurosurg. 2018; 122:e461-e466. DOI: 10.1016/j.wneu.2018.10.075. View

Soubannier V, Stifani S . NF-κB Signalling in Glioblastoma. Biomedicines. 2017; 5(2). PMC: 5489815. DOI: 10.3390/biomedicines5020029. View

Arshad H, Ahmad Z, Hasan S . Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev. 2011; 11(6):1637-40. View

Zhang X, Song Y, Song N, Zhang L, Wang Y, Li D . Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis. Braz J Med Biol Res. 2018; 51(3):e6265. PMC: 5769752. DOI: 10.1590/1414-431X20176265. View

Davis M . Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016; 20(5 Suppl):S2-8. PMC: 5123811. DOI: 10.1188/16.CJON.S1.2-8. View

Martinez-Garcia M, Alvarez-Linera J, Carrato C, Ley L, Luque R, Maldonado X . SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol. 2017; 20(1):22-28. PMC: 5785619. DOI: 10.1007/s12094-017-1763-6. View

Mecca C, Giambanco I, Donato R, Arcuri C . Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. Int J Mol Sci. 2018; 19(1). PMC: 5796261. DOI: 10.3390/ijms19010318. View

Neumann H, Takahashi K . Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol. 2007; 184(1-2):92-9. DOI: 10.1016/j.jneuroim.2006.11.032. View

10.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

11.

Walter J . The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. J Biol Chem. 2015; 291(9):4334-41. PMC: 4813462. DOI: 10.1074/jbc.R115.704981. View

12.

Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S . Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006; 12(12):1372-9. DOI: 10.1038/nm1518. View

13.

de Groot A, Appelman-Dijkstra N, van der Burg S, Kroep J . The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review. Cancer Treat Rev. 2017; 62:18-28. DOI: 10.1016/j.ctrv.2017.10.010. View

14.

Boyce B, Xing L . Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 Suppl 1:S1. PMC: 1924516. DOI: 10.1186/ar2165. View

15.

Zajkowicz A, Gdowicz-Klosok A, Krzesniak M, Janus P, Lasut B, Rusin M . The Alzheimer's disease-associated TREM2 gene is regulated by p53 tumor suppressor protein. Neurosci Lett. 2018; 681:62-67. DOI: 10.1016/j.neulet.2018.05.037. View

16.

Kim J, Jin X, Sohn Y, Jin X, Jeon H, Kim E . Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Cancer Lett. 2014; 353(2):194-200. DOI: 10.1016/j.canlet.2014.07.034. View

17.

Schoppet M, Preissner K, Hofbauer L . RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22(4):549-53. DOI: 10.1161/01.atv.0000012303.37971.da. View

18.

Naumnik W, Plonska I, Ossolinska M, Niklinski J, Naumnik B . Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer. Adv Exp Med Biol. 2017; 1047:1-6. DOI: 10.1007/5584_2017_111. View

19.

Prionisti I, Buhler L, Walker P, Jolivet R . Harnessing Microglia and Macrophages for the Treatment of Glioblastoma. Front Pharmacol. 2019; 10:506. PMC: 6560150. DOI: 10.3389/fphar.2019.00506. View

20.

Renema N, Navet B, Heymann M, Lezot F, Heymann D . RANK-RANKL signalling in cancer. Biosci Rep. 2016; 36(4). PMC: 4974605. DOI: 10.1042/BSR20160150. View